Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patient

International Journal of Gynecological Cancer

Volumn 23, Issue 4, 2013, Pages 673-679

  Chung, Ye Won ^a   Bae, Hyo Sook ^a   Song, Jae Yun ^a   Lee, Jae Kwan ^a   Lee, Nak Woo ^a   Kim, Tak ^a   Lee, Kyu Wan ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Biological markers; MicroRNAs; Ovarian neoplasms

Indexed keywords

MICRORNA; MICRORNA 132; MICRORNA 143; MICRORNA 145; MICRORNA 26A; MICRORNA LET 7B; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASCITES; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTADENOCARCINOMA; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN MICROARRAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TISSUE MICROARRAY; UPREGULATION;

ADULT; AGED; ASCITES; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84879917014     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31828c166d     Document Type: Article

References (25)

1. Häusler SF, Keller A, Chandran PA, et al. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer. 2010;103:693-700.
2. Resnick KE, Alder H, Hagan JP, et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009;112:55-59.
3. Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005;15:679-691.
4. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009;27:5848-5856.
5. Chin LJ, Slack FJ. A truth serum for cancer - microRNAs have major potential as cancer biomarkers. Cell Res. 2008;18:983-984.
6. Lodes MJ, Caraballo M, Suciu D, et al. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PloS One. 2009;4:e6229.
7. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513-10518.
8. Balch C, Fang F, Matei DE, et al. Minireview: epigenetic changes in ovarian cancer. Endocrinology. 2009;150:4003-4011.
9. Ambs S, Prueitt RL, Yi M, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008;68:6162-6170.
10. Knouf EC, Garg K, Arroyo JD, et al. An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription. Nucleic Acids Res. 2012;40:499-510.
11. Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353:1793-1801.
12. Dahiya N, Sherman-Baust CA, Wang TL, et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PloS One. 2008;3:e2436.
13. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67:8699-8707.
14. Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008;14:2690-2695.
15. Zhang L, Volinia S, Bonome T, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A. 2008;105:7004-7009.
16. Formosa A, Lena AM, Markert EK, et al. DNA methylation silences miR-132 in prostate cancer.Oncogene.2013;32:127-134.
17. Zhang S, Hao J, Xie F, et al. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis. 2011;32:1183-1189.
18. Anand S, Majeti BK, Acevedo LM, et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med. 2010;16:909-914.
19. Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361:1437-1447.
20. Dang X, Ma A, Yang L, et al. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet. 2012;205:113-123.
21. Helland Å, Anglesio MS, George J, et al. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PloS One. 2011;6:e18064.
22. Yang N, Kaur S, Volinia S, et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 2008;68: 10307-10314
23. Suzuki HI, Yamagata K, Sugimoto K, et al. Modulation of microRNA processing by p53. Nature. 2009;460:529-533.
24. Shi B, Sepp-Lorenzino L, Prisco M, et al. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem. 2007;282:32582-32590.
25. Lui WO, Pourmand N, Patterson BK, et al. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 2007;67:6031-6043.